Variasi Temperatur Pencampuran Terhadap Parameter Marshall Pada Campuran Lapis Aspal Beton

This study was conducted to determine the effect of temperature variations on the mixing processof the asphalt concrete AC-WC (Asphalt Concrete-Wearing Course) subtle gradations in themiddle limit and lower limit of the Marshall parameters with reference to specifications of BinaMarga, 2010.From the results of experiments conducted that the optimum asphalt content is used to middle limitusing a asphalt content of 5,7% and 6,8% for the lower limit after that mixing was done usingtemperature variation of 120 o C, 130 o C, 140 o C, 150 o C, and 160 o C.To a mixture of Laston AC-WC subtle gradations middle limit grading 5,7% asphalt contentmixing temperature using a temperature of 120 o C, 130 o C, 140 o C, 150 o C, 160 o C and still meet allstandards of marshall parameters. Ideal mixing temperature variations in the middle limit ofmixing temperature 150 o C-160 o C. While the lower limit to the level of 6,8% asphalt contentmixing temperatures between 120 o C-160 o C did not meet the specifications, because the MQ valuebelow the minimum value of 250 kg / mm

Functional annotation of the DEGs in SSD and MDD.

<p>(A) and (C) Pathway analysis of SSD-associated and MDD-associated genes respectively. The y-axis shows the KEGG Pathway terms, and the x-axis shows the enrichment significance P-values for the top 10 enriched Pathway terms. (B) and (D) GO analysis of SSD-associated and MDD-associated genes respectively. The y-axis shows the GO terms, and the x-axis shows the enrichment significance P-values for the top 10 enriched GO terms. Term GO:0004719 remarks the function of protein-L-isoaspartate (D-aspartate) O-methyltransferase activity. MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression.</p

Janus PEG-Based Dendrimers for Use in Combination Therapy: Controlled Multi-Drug Loading and Sequential Release

The increasing use of drug combinations to treat disease states, such as cancer, calls for improved delivery systems that are able to deliver multiple agents. Herein, we report a series of novel Janus dendrimers with potential for use in combination therapy. Different generations (first and second) of PEG-based dendrons containing two different “model drugs”, benzyl alcohol (BA) and 3-phenylpropionic acid (PPA), were synthesized. BA and PPA were attached via two different linkers (carbonate and ester, respectively) to promote differential drug release. The four dendrons were coupled together via (3 + 2) cycloaddition chemistries to afford four Janus dendrimers, which contained varying amounts and different ratios of BA and PPA, namely, <b>(BA)</b>_<b>2</b><b>-G1-G1-(PPA)</b>_<b>2</b>, <b>(BA)</b>_<b>4</b><b>-G2-G1-(PPA)</b>_<b>2</b>, <b>(BA)</b>_<b>2</b><b>-G1-G2-(PPA)</b>_<b>4</b>, and <b>(BA)</b>_<b>4</b><b>-G2-G2-(PPA)</b>_<b>4</b>. Release studies in plasma showed that the dendrimers provided sequential release of the two model drugs, with BA being released faster than PPA from all of the dendrons. The different dendrimers allowed delivery of increasing amounts (0.15–0.30 mM) and in exact molecular ratios (1:2; 2:1; 1:2; 2:2) of the two model drug compounds. The dendrimers were noncytotoxic (100% viability at 1 mg/mL) toward human umbilical vein endothelial cells (HUVEC) and nontoxic toward red blood cells, as confirmed by hemolysis studies. These studies demonstrate that these Janus PEG-based dendrimers offer great potential for the delivery of drugs via combination therapy

Mostly potential signatures of gene expression profiles models for classification of MDD and SSD.

<p>MDD: Major depression disorder; SSD: Subsyndromal symptomatic depression; HC: Healthy controls.</p

Mostly potential pathways of disorder model biomarker.

<p>Mostly potential pathways of disorder model biomarker.</p

The relationship between depression/anxiety severity and genes expression profiles (STRN, CD84 and CTNS) in SSD patients.

<p>The relationship between depression/anxiety severity and genes expression profiles (STRN, CD84 and CTNS) in SSD patients.</p

Differential gene expression in patients with subsyndromal symptomatic depression and major depressive disorder

<div><p>Background</p><p>Subsyndromal symptomatic depression (SSD) is a subtype of subthreshold depressive and can lead to significant psychosocial functional impairment. Although the pathogenesis of major depressive disorder (MDD) and SSD still remains poorly understood, a set of studies have found that many same genetic factors play important roles in the etiology of these two disorders. Nowadays, the differential gene expression between MDD and SSD is still unknown. In our previous study, we compared the expression profile and made the classification with the leukocytes by using whole-genome cRNA microarrays among drug-free first-episode subjects with SSD, MDD and matched healthy controls (8 subjects in each group), and finally determined 48 gene expression signatures. Based on these findings, we further clarify whether these genes mRNA was different expressed in peripheral blood in patients with SSD, MDD and healthy controls (60 subjects respectively)</p><p>Method</p><p>With the help of the quantitative real-time reverse transcription-polymerase chain reaction (RT-qPCR), we gained gene relative expression levels among the three groups.</p><p>Results</p><p>We found that there are three of the forty eight co-regulated genes had differential expression in peripheral blood among the three groups, which are CD84, STRN, CTNS gene (F = 3.528, <i>p</i> = 0.034; F = 3.382, <i>p</i> = 0.039; F = 3.801, <i>p</i> = 0.026, respectively) while there were no significant differences for other genes.</p><p>Conclusion</p><p>CD84, STRN, CTNS gene may have significant value for performing diagnostic functions and classifying SSD, MDD and healthy controls.</p></div